J. S. McLellan

The paper maps antibody sequences to antigen specificity across multiple viral antigens, identifying convergent sequence features in antiviral B cells.

This study compares IgG antibody responses from SARS-CoV-2 infection, vaccination, and hybrid immunity, finding that hybrid immunity retains the imprint of the initial exposure and enhances antibody breadth and affinity.

This study shows that Omicron variant-matched boosters after prototype mRNA vaccines induce cross-neutralizing antibodies against SARS-CoV-2 and sarbecoviruses by imprinting prior immune responses.

This study designs stabilized SARS-CoV-2 S2 immunogens using simulation-driven approaches, showing improved stability and immunogenicity.

The paper identifies a conserved neutralizing epitope on the S2 domain of SARS-CoV, SARS-CoV-2, and MERS-CoV spike proteins that is targeted by antibody 3A3.

The paper identifies conserved S2-domain antibody responses in anamnestic immunity across SARS-CoV-2 variants, suggesting their role in viral clearance and vaccine design.

This study characterizes prefusion-F-specific antibodies from elderly individuals naturally infected with hMPV, revealing their epitope recognition and neutralizing activity.

This study identifies Pro1261 in the RSV polymerase as critical for RNA synthesis initiation, unlike a corresponding residue in a filovirus polymerase.

This study identifies a potent monoclonal antibody against hMPV and determines its structure, revealing a novel epitope for therapeutic development.

This paper identifies NTD-targeting neutralizing antibodies and shows that combining RBD and NTD antibodies reduces the emergence of neutralization-escape mutants.

This study reveals how EBV's BORF2 protein inhibits APOBEC3B by blocking its access to DNA, providing insights for drug development.

The paper identifies an alternative open-trimer conformation of the SARS-CoV-2 spike ectodomain that exposes novel epitopes and is modulated by temperature, binding, and sequence variants.

This study demonstrates that integrating ligand blocking into LIBRA-seq improves the efficiency of identifying potent SARS-CoV-2 neutralizing antibodies.

This study identifies a potent SARS-CoV-2 antibody, 54042-4, that neutralizes variants of concern and has a unique epitope and genetic structure.

The paper profiles early humoral immune responses in COVID-19 patients, finding that survivors show rapid SARS-CoV-2-specific immunity linked to pre-existing OC43 immunity, while non-survivors have delayed and blunted responses.

This study determines the cryo-EM structure of HCMV Pentamer bound to neuropilin 2 and neutralizing antibodies, revealing molecular interactions and epitopes involved in viral tropism and neutralization.

This study shows that a SARS-CoV-2 RBD nanoparticle vaccine protects against SARS-CoV-2 and related sarbecoviruses, including variants, in mice and non-human primates.

This study identifies a glycan gate and key residues that facilitate SARS-CoV-2 spike protein RBD opening through simulations and experimental validation.

This study shows that three mutations in SARS-CoV-2 allowed it to escape neutralization by a highly neutralizing convalescent plasma.

The paper identifies prevalent, protective, and convergent IgG antibodies targeting non-RBD epitopes of SARS-CoV-2 spike protein in convalescent plasma.

The paper identifies cross-reactive antibodies against multiple coronaviruses, showing they target diverse epitopes and mediate effector functions.

This study engineers an antibody, ADG-2, that broadly neutralizes SARS-CoV and SARS-CoV-2 in mice, offering protection against respiratory disease and viral replication.

This paper describes a scalable method to produce high-quality trimeric SARS-CoV-2 Spike proteins for vaccines and diagnostics.

This study reveals the structural role of glycans in modulating SARS-CoV-2 spike protein conformational dynamics and ACE2 binding through molecular simulations and experiments.

This study designs and characterizes prefusion-stabilized SARS-CoV-2 spike variants to improve protein yield and stability for vaccine and diagnostic development.

The paper identifies broadly neutralizing antibodies against SARS-CoV-2 and related sarbecoviruses, highlighting a conserved epitope on the spike protein as a potential vaccine target.

The paper introduces local computational methods to improve cryo-EM map interpretability by avoiding over-sharpening and providing local B-factors and occupancy maps.

This study isolates and characterizes VHH antibodies that neutralize MERS-CoV, SARS-CoV-1, and SARS-CoV-2 by blocking receptor binding, with structural insights into their epitopes and cross-reactivity.

The paper uses mass spectrometry to analyze glycan structures on the SARS-CoV-2 spike protein, revealing differences from host glycan processing and implications for vaccine design.